Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks,.
ASLAN Pharmaceuticals (ASLN) Reports Eblasakimab Monthly Dosing Shows Potential for Best-In-Class Therapy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ASLAN will receive up to $15 million in upfront and near-term payments and up to an additional $123.5 million based on development and commercial milestones plus tiered royalties on sales in percentages ranging up to low twentiesZenyaku Kogyo, a leading J.
01.06.2023 - SAN MATEO, Calif. and SINGAPORE, June 01, 2023 (GLOBE NEWSWIRE) - ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today .
Data readout for TREK-AD Phase 2b study of eblasakimab on track for early July 2023Four abstracts on eblasakimab and farudodstat, including two late-breakers, to be presented at the 1st International Societies